Alterity Therapeutics Limited (ATHE)
| Market Cap | 81.15M +83.2% |
| Revenue (ttm) | 3.69M +78.2% |
| Net Income | -16.19M |
| EPS | -0.08 |
| Shares Out | 217.51M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,729 |
| Open | 4.540 |
| Previous Close | 4.560 |
| Day's Range | 4.460 - 4.830 |
| 52-Week Range | 2.660 - 5.892 |
| Beta | -0.04 |
| Analysts | Strong Buy |
| Price Target | 13.25 (+193.79%) |
| Earnings Date | Aug 31, 2026 |
About ATHE
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson’s disease. The company’s lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson’s disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as we... [Read more]
Financial Performance
In fiscal year 2025, Alterity Therapeutics's revenue was 5.44 million, an increase of 35.32% compared to the previous year's 4.02 million. Losses were -12.15 million, -36.48% less than in 2024.
Financial numbers in AUD Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for ATHE stock is "Strong Buy." The 12-month stock price target is $13.25, which is an increase of 193.79% from the latest price.
News
Alterity Therapeutics Annual report: H2 2026
Alterity Therapeutics has published its H2 2026 annual report on August 27, 2026.
Alterity Therapeutics granted new patent for ATH434
Alterity Therapeutics (ATHE) announced that the United States Patent and Trademark Office has granted a new composition of matter patent for ATH434, the company’s lead clinical asset. ATH434 is an…
Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434
– Newly granted patent extends protection for ATH434 to at least 2045, significantly enhancing its strategic value and long-term commercial potential –
Alterity Therapeutics Transcript: Canaccord Genuity's 46th Annual Growth Conference
ATH434 slowed MSA progression by up to 50% in phase II, with strong efficacy in mobility and swallowing endpoints and a favorable safety profile. Phase III is set for 2024 with FDA alignment, targeting a $2.4 billion market and significant unmet need.
Alterity Therapeutics (ATHE) Rated Buy by Craig-Hallum Amid Phase 3 Trial Optimism
Alterity Therapeutics (ATHE) Rated Buy by Craig-Hallum Amid Phase 3 Trial Optimism
Craig-Hallum bullish on Alterity Therapeutics, initiates with a Buy
As previously reported, Craig-Hallum initiated coverage of Alterity Therapeutics (ATHE) with a Buy rating and $12 price target The firm sees Alterity as a high-risk/high-reward setup around ATH434 in ...
Alterity Therapeutics initiated with a Buy at Craig-Hallum
Craig-Hallum analyst Adam Vogel initiated coverage of Alterity Therapeutics (ATHE) with a Buy rating and $12 price target
Alterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth Conference
MELBOURNE, Australia and SAN FRANCISCO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update
Highlights FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA) FDA agreed that a single pivotal Phase 3 trial plus confirmatory evi...
Alterity Therapeutics Earnings release: Q4 2026
Alterity Therapeutics released its Q4 2026 earnings on July 29, 2026, summarizing the period's financial results.
Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026
MELBOURNE, Australia and SAN FRANCISCO, July 21, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Alterity To Initiate Phase 3 Trial Of ATH434 In MSA Subsequent To Receipt Of EOP2 Minutes From FDA
(RTTNews) - Alterity Therapeutics Ltd. (ATHE), a clinical-stage biotechnology company, announced that it has received the U.S. Food and Drug Administration's meeting minutes from the End-of Phase 2 or...
Alterity Therapeutics (ATHE) Faces 8.8% Decline Ahead of Market Open
Alterity Therapeutics (ATHE) Faces 8.8% Decline Ahead of Market Open
Alterity Therapeutics (ATHE) Advances Towards Phase 3 Trial Approval
Alterity Therapeutics (ATHE) Advances Towards Phase 3 Trial Approval
Alterity Therapeutics receives FDA meeting minutes on pathway for ATH434
Alterity Therapeutics (ATHE) announced that it has received the official meeting minutes from its End-of Phase-2 meeting for ATH434 in Multiple System Atrophy from the FDA. The minutes confirm the…
Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy
– Official FDA minutes confirm the previously announced End-of-Phase 2 meeting outcomes and provide additional detail on the planned Phase 3 protocol —
Alterity Therapeutics initiated with a Buy at JonesResearch
JonesResearch initiated coverage of Alterity Therapeutics (ATHE) with a Buy rating and $16 price target Alterity’s oral iron chaperone, ATH434, is set to enter Phase 3 development for multiple system…
Alterity Therapeutics assumed with a Buy at Ladenburg
Ladenburg analyst Caroline Palomeque assumed coverage of Alterity Therapeutics (ATHE) with a Buy rating and $10 price target Alterity is entering late-stage clinical development which “is an ideal tim...
Alterity Therapeutics Slides: Corporate presentation
Alterity Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 15, 2026.
Alterity Therapeutics achieves alignment with FDA on program for ATH434 in MSA
Alterity Therapeutics (ATHE) announced the outcome of its End-of-Phase 2 meeting with the FDA, achieving alignment on the elements of the company’s registrational Phase 3 program for ATH434 in Multipl...
Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy
– Successful End-of-Phase 2 meeting with FDA agreeing on key elements of the proposed Phase 3 design, including study population, dosing regimen, and treatment duration –
Alterity Therapeutics management to meet with BTIG
Meeting to be held in San Francisco on June 10-11 hosted by BTIG.
Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
– Alterity's novel imaging and biomarker approach positions the Company at the forefront of clinical research in MSA –
Alterity Therapeutics publishes quantitative susceptibility mapping MRI data
Alterity Therapeutics (ATHE) announced the publication of a peer-reviewed study in NeuroImage, demonstrating that quantitative susceptibility mapping MRI can detect disease-specific iron accumulation ...
Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
– Peer-reviewed study from the bioMUSE Natural History Study shows advanced MRI method detects disease-specific iron accumulation that supports diagnosis and correlates with clinical severity in patie...